Ladies and gentlemen, thank you for standing by. Hello, and welcome to the conference call hosted by Daré Bioscience to review the company's first quarter 2026 financial results and to provide a business update. This call is being recorded. My name is King, and I will be your operator today. With us today from Daré are Sabrina Martucci Johnson, President and Chief Executive Officer, and MarDee Haring-Layton, Chief Accounting Officer. Ms. Haring-Layton, please proceed. Good afternoon, welcome to the Daré Bioscience financial results and business update call for the quarter ended March 31st, 2026. Today, we will review our financial results, provide updates on our clinical pipeline, and discuss the continued execution of our expanded business strategy. That strategy includes a dual path approach, commercializing proprietary formulations through 503B compounding while pursuing FDA approval and advancing select solutions as branded consumer health products that do not require a prescription. In all cases, our goal is to bring innovative women's health solutions to market as efficiently and quickly as possible. I would like to remind you that today's discussion will include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical fact should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by the cautionary statements in the company's SEC filings, including our quarterly report on Form 10-Q for the quarter ended March 31st, 2026, which was filed today, and our annual report on Form 10-K for the year ended December 31st, 2025. Please note that in the context of this call includes time-sensitive information that is current only as of today, May 14, 2026. Daré undertakes no obligation to update any forward-looking statements to reflect new information or developments after this call, except as required by law. I would also like to point out that when we use the term 503B compounding during this discussion, we are referring to compounding drug products by outsourcing facilities registered under Section 503B of the Federal Food, Drug, and Cosmetic Act using bulk drug substances on the FDA's interim Category 1 list. I will now turn the call over to Sabrina. Great. Thank you, MarDee, and good afternoon, everyone, and thank you for joining us. I am taking the call today from N.Y. in the middle of National Women's Health Week, and this year's theme, which is Prevention, Innovation, and Impact, A New Era in Women's Health, couldn't be more relevant to our discussion this afternoon. Daré was built on the conviction that women's health is an investment-grade category, not a niche, not a nice-to-have, not a pink ribbon in a press release. It's a category worth building, funding, and holding accountable for delivering to women the healthcare options they deserve. That is exactly what we're doing today and reporting on what we've built and where we're going. Over 10 years ago, we made a decision to focus exclusively on women's health, as you know, not as a sideline, not as a franchise within a broader portfolio, as our entire reason for existing. Every dollar raised, every clinical trial run, every regulatory submission prepared, every partnership negotiated, all of it for one purpose, building the company with the most comprehensive pipeline comprised exclusively of differentiated products for health issues and conditions that uniquely impact women. From contraception to menopause, sexual health to fertility, vaginal health to human papillomavirus, we're working to close critical gaps in care with science that meets her needs. What distinguishes Daré is not just the breadth of the pipeline, but the strategy behind it. That disciplined approach to capital allocation that pairs non-dilutive grant funding with focused development, so that we can move multiple programs towards the clinic simultaneously. It's not a single product bet. It's a portfolio of strategies. It's built from the ground up for one of the most chronically underfunded areas in all of medicine, despite affecting half the world's population. We're not a company that's just getting into women's health. What 10 years of commitment looks like is what is coming into view right now. I also want to be precise about what kind of company Daré is because the women's health space is attracting more and more entrants, and not all of them are building the same thing. This is a growing category of women's health platform companies that offer services, telehealth subscriptions, care navigation, clinical memberships. That's what's happening, and they make products available as part of the service experience. We respect those companies and what they're doing, but that is not what Daré is. Daré is a product company. Our mission is to develop and bring to market clinically studied, differentiated women's health products with real data behind them, addressing gaps where, in our view, nothing adequate exists today. The DARE Health Hub and telehealth access we provide, they're infrastructure built to put those products in the hands of women efficiently. Access is essential, but the products are the point, and that distinction matters, especially for clinicians. When a provider writes a prescription for DARE to PLAY, they are prescribing a specific formulation with published clinical data. Not some generic compounded product and not a service bundle. We're building relationships with the clinical community that are grounded in the credibility of what's in our tubes or bottles. That's a very different conversation than one built around a subscription platform. To our knowledge, Daré Bioscience has the most robust development stage pipeline of any company in the world developing products exclusively for conditions that solely affect women. We have not been able to identify a company with a comparable portfolio. Products are protectable. Products can generate recurring product revenue. Products can be partnered. Products can be approved by the FDA. Products can be real-world solutions. A great way to illustrate our product model is to start with DARE to PLAY. Since our last call, one of the most meaningful events we participated in was the American College of Obstetricians and Gynecologists, or ACOG, their annual conference. I want to share what happened there because I believe it signals something important about where DARE to PLAY is headed. The reception we received at ACOG for DARE to PLAY was enthusiastic. Healthcare providers attending, and that includes OB/GYNs, women's health specialists, sexual health clinicians, they were genuinely excited about the product. I mean, genuinely, we literally had providers who were so enthusiastic about DARE to PLAY that they were writing prescriptions for each other on the spot at the booth. That's not a marketing antidote. That's a signal. When experienced clinicians who see patients every single day, and have long lamented the absence of evidence-based options for women's sexual health, they see DARE to PLAY and immediately want it for themselves and their patients. It tells you something real about the unmet need and the credibility of our product. We also had clinicians approach us about stocking DARE to PLAY directly in their offices. That level of interest from the provider community is exactly what a new prescription option needs to build sustainable momentum, and we are actively working to support those discussions. Providers are becoming advocates. That's how sustainable commercial momentum is built, not just relying on advertising, but through clinician conviction. DARE to PLAY is a first of its kind topical arousal cream for women. To our knowledge, there is no other sildenafil topical cream manufactured under good manufacturing practice requirements with clinical data demonstrating increased genital blood flow in 10 to 15 minutes and improvements in arousal, orgasm, desire as measured by clinically validated and FDA-reviewed endpoints. As we've discussed before, men have had Viagra in their medicine cabinet for over 25 years. Women have not had a sildenafil cream formulation clinically studied and developed specifically for them until now. An estimated 20 million women in the U.S. report challenges related to genital arousal, there's not a single FDA-approved therapy that directly addresses the need, not one. While there's not yet an FDA-approved therapy, DARE to PLAY was designed to fill the void. As Marty mentioned up front, we are making DARE to PLAY available as a Section 503B compounded product. I want to reiterate again what we hear from healthcare providers and women because they continue to tell us the same three things about DARE to PLAY that uniquely resonates with them. It works fast. It was genuinely built by biotech and studied for them. We also hear that following those good manufacturing practices around potency and quality guidelines so they know exactly what they're getting every single time is important. These are not baseless statements. They're what clinical data show and what compliance with GMP requirements validates. The pre-fulfillment prescribing for DARE to PLAY sildenafil cream, as you know, has been live across 50 states since February 2026. The clinician response we continue to see is encouraging. Bravado, the 503B-registered outsourcing facility for DARE to PLAY, they're targeting dispensing to begin this summer as they continue to complete the necessary state licensing and fulfillment preparations. It's a significant milestone that we have been building toward. Our 503B commercial model is asset light and digitally native by design. We drive that consumer awareness through targeted digital marketing. Women can access DARE to PLAY through telehealth without an in-person offce visit. It's a discreet, convenient option. Medvantx handles the fulfillment and dispensing through the DARE Health Hub with the quality infrastructure they already have in place. I want to reiterate again about how we think about telehealth in our model. Telehealth is an access infrastructure. It's a critical tool for getting our products to the women who need them, but it's not the business model. We're not a subscription service. We're not a care navigation platform with the burdens that those bring. We're a product company. We're using telehealth as one channel among several to deliver clinically studied, differentiated solutions efficiently. That's also why the provider relationship matters so much to us. Healthcare providers, again, the OB/GYNs, the women's health specialists, the primary care physicians, are not a channel to us. They are our clinical partners. When we say DARE to PLAY was built specifically for women and has been clinically studied in women, that means to a provider in a way that a generic compounded cream does not. When a clinician at ACOG asks how to stock our product in her office, she's not asking about a service. She's asking about a product she believes in, and she wants to offer her patients directly. That's the kind of relationship we're building, and it's built on the credibility of the product itself. As we prove out what it costs to acquire a patient digitally and how long they stay on the product, and as dispensing commences this summer, we can add channels and scale to spend accordingly. As our commercial footprint grows, we expect additional strategic collaborations with telehealth provider platforms, right, other ones, platform distributors, and clinical networks, all in the service of getting our products to more women faster. Stay tuned. Here's what makes our approach uniquely powerful. While DARE to PLAY is available for pre-fulfillment today through that 503B compounding pathway, generating real prescribing data, building clinician relationships, and creating that patient demand, we are simultaneously working to advance our sildenafil cream towards the 505B2 NDA pathway for FDA approval. Both can happen at the same time, and that's the power of building our products around well-characterized chemical entities, compounds with established safety databases. We can start building a market for certain of our product candidates. We build that market while we build the regulatory file and the real-world data we generate through the 503B strategy may ultimately strengthen our NDA submission. To our knowledge, there is no company our size in women's health that has this kind of strategic flexibility, and it's a result of how deliberately we designed our pipeline. I want to take a moment to highlight what I believe is an underappreciated milestone for Daré, and one that'll mark the second quarter as a milestone for our company. Flora Sync LF5, which is our first DARE to RESTORE vaginal probiotic suppository that we are launching commercially in June 2026. Seeding campaigns, these are things designed to build clinician awareness and drive initial consumer trial. Those are beginning now in May ahead of that commercial launch. We begin to expect recording revenue from Flora Sync LF5 in June. This will mark the first time that we have recorded direct product revenue as a company. It is a big milestone for our company, and one that we believe changes how investors should think about our story. The DARE to RESTORE products are probiotics designed to support vaginal microbiome balance. Flora Sync LF5 is a vaginal probiotic suppository developed by Probiotical, one of the world's leading probiotic research companies. The formulation is based on scientific research into vaginal microbiome composition and health. It's been studied in a 100-person clinical trial, and the findings have been published in a peer-reviewed journal. Probiotical is the exclusive manufacturer using its proprietary LF5 strain. We believe that level of clinical evidence distinguishes Flora Sync LF5 from the majority of vaginal probiotic suppositories on the market today, and we expect it to be an important differentiator as we build the DARE to RESTORE brand. We intend to distribute DARE to RESTORE products through the DARE Health Hub, where we believe they will be complementary to our 503B prescription offerings. Healthcare providers may recommend DARE to RESTORE products alongside DARE to PLAY or other Daré products as part of a comprehensive approach to women's vaginal and sexual health. Intimacy and intercourse can be one of the biggest disruptors of the vaginal microbiome. DARE to RESTORE Flora Sync LF5 is a reset and reconnect solution focused on balance, confidence, comfort, and intimacy wellness. Next, I'll walk you through other program updates and milestones we're targeting for 2026 and 2027. DARE to RECLAIM is our proprietary monthly intravaginal ring designed to deliver bioidentical estradiol and progesterone, targeting the estimated $2.5 billion-$4.5 billion compounded hormone therapy market. Women are demanding alternatives to synthetic hormones. Bioidentical hormone therapy is a category on the rise, particularly with the removal of the black box warning. We expect DARE to RECLAIM to be the first monthly intravaginal delivery solution in this space, combining bioidentical estradiol and bioidentical progesterone. We're targeting to have DARE to RECLAIM available for 503B prescription fulfillment in 2027, while simultaneously pursuing activities to support an NDA filing and a pivotal phase III clinical study utilizing the dual-pass strategy. Imagine the first monthly bioidentical hormone therapy IVR, including both estradiol and progesterone together, in an estimated $2.5 billion-$4.5 billion market. That's what DARE to RECLAIM is positioned to be, and investors can invest in that potential today. Ovaprene. Ovaprene is our monthly intravaginal hormone candidate, and earlier this week, we announced positive interim results from our ongoing phase III clinical trial, and that's following the second planned interim analysis by the trial's independent data safety monitoring board, or DSMB. The DSMB reviewed interim data and recommended the study continue without modification for the second time. This second consecutive positive DSMB review reinforces Ovaprene's potential as a meaningful hormone-free contraceptive alternative as it advances through its phase III trial. The interim data show that approximately 9% of women treated in the study had experienced a pregnancy. That rate is consistent with our expectations based on the results of the pre-pivotal postcoital test clinical study, as well as the last DSMB meeting. There are no new types of adverse events or tolerability concerns identified. Neither an increase nor decrease in the frequency of adverse events, nor the emergence of new types of adverse events was observed with prolonged Ovaprene use. Approximately 12% of participants discontinued the study due to vaginal odor. That's the most commonly reported product-related adverse event. That rate, though, is a 5% decrease compared to the data reviewed by the DSMB last summer in July of 2025. No serious adverse events related to the study device were identified, and a majority of the participants who completed the study reported that they would be very likely or likely to use Ovaprene if it became available. The DSMB reviewed data from almost 400, from 340 study subjects, contributing nearly 1,800 menstrual cycles of safety data, and that's a meaningful proportion of the study's 2,500- cycle target. The study protocol calls for at least 2,500 cycles of exposure and 250 subjects completing 13 menstrual cycles of use. Based on the current enrollment trends, we would expect to achieve the 2,500 cycles of exposure before 250 subjects complete 13 menstrual cycles of use. Importantly, the interim safety data suggests that prolonged product use was not associated with the emergence of new types of adverse events or an increased frequency of adverse events, and we believe that may support the sufficiency of fewer than 250 subjects completing 13 cycles to evaluate Ovaprene's safety profile. We do intend to engage with the FDA regarding these findings. That's two consecutive positive DSMB reviews on Ovaprene and a pregnancy rate consistent with expectations, tolerability data that improved from the first interim look, and a majority of users who say they would use it again. That's a differentiated potential first-in-category asset advancing through its pivotal clinical trial. There are currently no FDA-approved hormone-free monthly intravaginal contraceptives, and a growing number of women, particularly younger women, are actively seeking alternatives to hormonal contraceptive. Ovaprene is designed to be the answer. We currently expect to complete enrollment sufficient to achieve at least 2,500 cycles of exposure in 2026, and completing enrollment in 2026 puts the primary endpoint analysis within reach in 2027. Now a little bit about DARE-HPV. DARE-HPV is perhaps our most underappreciated development program. An estimated 6 million women in the U.S. alone acquire a high-risk HPV infection every single year, and today, every single one of them is being managed with watchful waiting or surgery. There is no drug therapy. That represents a completely untreated patient population with a clear clinical need and no existing direct competition in the pharmacologic space. High-risk HPV types are the underlying cause of virtually all cervical cancer cases in the U.S., 99% of them. For decades, women with persistent high-risk HPV infection have been told to watch and wait, to monitor and hope that the virus clears on its own. If it doesn't, the only recourse has been surgery once those precancerous changes appear. As I mentioned, there's not a single FDA-approved pharmacologic treatment for high-risk HPV infection, not one. We're developing one with ARPA-H funding. With that ARPA-H funding, FDA clearance of our IND application, which happened in February of this year, we are now preparing to advance DARE-HPV into a phase II clinical study in May, this month. DARE-HPV has the potential to be the first pharmaceutical therapeutic in one of the largest unaddressed infectious disease markets affecting women globally. Significant addressed market, grant-funded development, advancing into phase II clinical development. That's exactly the kind of asset that gets re-rated when investors discover it, and we believe very few have. Other potential first-in-category contraceptive candidates that we are currently developing are supported entirely with grant funding. That's DARE-LARC1, Casea S3, and DARE-NHC. They all are continuing to advance. We also have an extended NIH-funded award for DARE-PTB1, which is our bioidentical progesterone intravaginal ring candidate aiming to reduce the risk of preterm birth in at-risk women. The pipeline was deliberately built to address the most persistent gaps, from preterm birth to HPV-associated disease to sexual health and beyond. Every $1 of grant funding we secure, it's a $1 that moves us closer to putting better options in the hands of women without diluting our shareholders. I now want to speak directly to every investor on the call, institutional, retail, and anyone who's listening to the replay. As I mentioned upfront, I'm joining this call from and during the National Women's Health Week in New York. As I said up front, the context matters. Women's health is an investment-grade category, and we believe Daré is the investment-grade vehicle to capture what is still a dramatically underfunded opportunity. We're not here because it's the right week to say that. We're here because we have spent over 10 years proving it. We built the portfolio with clinical rigor, disciplined capital management, and that unwavering commitment to women who have been underserved by the healthcare system for far, far too long. Right now, in mid-2026, we're at that moment where all of that investment converges into action. The products are coming live, and we expect to record the first direct product revenue this quarter. Demand is building, the data are coming, and we're poised for partnerships. Women represent 1/2 of that global population. Approximately 80% of all U.S. healthcare purchasing decisions are made by women. Conditions that solely affect women, the very conditions for which we are developing treatments, they're attracting less than 1% of private healthcare investment. Women's health drugs represent 27% of all blockbuster pharmaceutical products, and that's not even including GLP-1s. That's not a niche. That's a market failure that created a gap, and that's the gap that Daré was built to address. I want to also address a question that we hear as we're approaching commercialization. I get asked, are we an R&D company or are we a commercial company? I answer, yes. We're in the business of getting first-in-category products into the hands of women who need them. That requires both. We will not stop developing. We have a pipeline that includes potential first-in-category programs across contraception, HPV, hormone therapy, and vaginal health, all advancing, many with non-dilutive funding. That R&D engine's running. Starting in June, that engine will be joined by a commercial engine, generating product revenue. Here's how I want investors to think about that. Product revenue is not a pivot. It's not a change of identity. It's another source of capital, and it's a value driver. Grant funding, equity financings, and now product revenue. They're three distinct complementary sources of capital that together let us continue building without depending on any one of them alone. We don't need to choose between R&D and commercial. We're building a company that does both because the women we're working for, they need both, the science and the products. We intend to deliver on both fronts simultaneously. Here's what we're targeting to deliver again as a recap. DARE to PLAY dispensing. We're targeting commencement nationally this summer via Bravado as our 503B outsourcing facility partner. DARE to RESTORE family, Flora Sync LF5 being the first such probiotic. The seeding campaigns are beginning this month in May. The commercial launch and first product revenue is expected in June. I want to reinforce an important first step in building a multi-product revenue profile for Daré. Additional DARE to PLAY collaborations, as I said, stay tuned. Commercial and telehealth collaborators to be announced as our channel infrastructure matures. DARE to RECLAIM dispensing. We are continuing to target 2027 for another 503B outsourcing facility with IND preparatory activities for what we've often referred to as DARE-HRT1, right, our hormone therapy product, ongoing pursuant to our dual path strategy. Ovaprene, again, I want to reiterate that second positive DSMB review just happened and was just announced this week. The enrollment expected to complete this year to achieve that 2,500 cycles of exposure. That puts 2027 primary endpoint analysis within reach. As I mentioned, we do plan on FDA engagement regarding those interim findings and study protocol. Then DARE-HPV, that phase II. We're preparing that right now with that ARPA-H funding. We're looking to start this month. Stay tuned on that. Hopefully, what you get with all of that is that we are not a single- event binary bet. It's a portfolio with multiple catalysts and multiple pathways to value, multiple ways to win. With every prescription written for DARE to PLAY, we're building the real- world data set. Every Ovaprene patient enrolled in our phase III moves us closer to data that will attract partners. Every clinician who prescribes one of our products can become an advocate for the next. We're building a platform, not just a single product. That year of clinical data on our specific formulations, that's data that a competitor can't replicate overnight. Established and growing relationships with telehealth providers, specialty pharmacies, clinical KOLs in women's sexual health and vaginal health right now, including that clinician community we engage with at ACOG. All the groundwork we're laying for the 505B2 regular pathway that we believe will provide an opportunity to protect our market position after the 503B market matures. The brands, DARE to PLAY, DARE to RESTORE, DARE to RECLAIM that we're talking about right now, they're built around a clear resonant identity with women. We're operating at a moment when the cultural and commercial conversation about women's health has never been louder. The femtech and women's health services sectors are attracting serious capital. Women are demanding that healthcare take their needs seriously. The rising tide is bringing many entrants, services, platforms, subscription models. There's real investment flowing in the category. We think that is a good thing for awareness. We also think it matters enormously what kind of company is doing the building. Services can be copied, subscriptions can be undercut, but clinical data, that speaks for itself. Products can be real- world solutions. We're a product company with a pipeline that is not reactive to a trend. We foresaw the trend, and it's exactly what the trend is calling for. As I said on the last earnings call, the tide is rising in women's health and Daré has been building its pipeline at low tide. Investors want to be in before the water rises are looking at our company right now. With that, I'll turn it over for Marty to give a financial review. Thanks, Sabrina. Good afternoon, everyone. I'll now walk through our financial results for the quarter ended March 31st, 2026, and provide context on our balance sheet and forward financial positioning. We ended the quarter with approximately $18.5 million in cash and cash equivalents and working capital of approximately half a million. As a reminder, we continue to benefit from meaningful non-dilutive capital sources that help us advance our pipeline. In 2025, we received approximately $13.6 million from the Gates Foundation, $4.5 million under our ARPA-H award, and $1.3 million from NIH grant reimbursements. In February 2026, we received an additional $2 million under our ARPA-H award. These sources have allowed us to advance multiple programs simultaneously while managing shareholder dilution responsibly. Selling, general, and administrative or SG&A expenses for the first quarter of 2026 were approximately $2.2 million, compared to approximately $2.3 million in the first quarter of 2025. The year-over-year decrease was primarily attributable to decreases in personnel costs, offset by increases in professional services and commercial readiness expenses, including preparations to bring DARE to PLAY and Flora Sync LF5 to market and stock-based compensation expense. Research and development or R&D expenses were approximately $0.7 million for the first quarter of 2026, compared to approximately $2.3 million in the first quarter of 2025. I want to again highlight an important feature of our R&D expense reporting. We recognize non-dilutive funding awards as contra R&D expense, meaning grant funding directly offsets our reported R&D costs. Contra R&D expense related to grant funding was approximately $3.5 million for the first quarter of 2026, compared to approximately $3.1 million for the first quarter of 2025. This means our actual total R&D investment when you add back contra R&D amounts is meaningfully greater than the R&D expense line alone reflects. We believe this is an important dynamic for investors to understand when evaluating the true scale of our R&D investment. We expect to begin recording product revenue from DARE to PLAY in the third quarter of 2026. Flora Sync LF5 consumer health product revenue is expected to begin in June 2026. We are targeting DARE to RECLAIM revenue to begin in 2027. We are building toward a multi-product revenue profile that diversifies and grows across 2026 and 2027. The initiation of direct product revenue in June 2026 for the first time in the company's history is a milestone we have worked hard to reach, and one that we are proud to be approaching. I want to offer our perspective on what product revenue means strategically. Daré has funded its development through a combination of equity financings and non-dilutive grant funding. Product revenue will add a third leg to that stool, a capital source tied directly to the value we are delivering to patients and clinicians, one that we expect to grow as our commercial footprint grows, and that reinforces the development mission rather than competing with it. We encourage investors to review the more detailed discussion of our financial statements, financial condition, liquidity, capital resources, and risk factors in our Form 10-Q for the quarter ended March 31st, 2026, filed today. Operator, please open the line for questions. Thank you so much, Marty. Just a quick reminder before we start the Q&A. If you would like to ask a question, please press star one on your telephone keypad to raise your hand and enter the queue. If you would like to withdraw your question, simply press star, one again. We will pause for a brief moment to wait for the questions to come in. Thank you. We will take our first question from the line of Kemp Dolliver from Brookline Capital Markets. Please go ahead. Great. Thank you. couple questions. first, with regard to the Ovaprene trial and the interplay between enrollment pace and cycles. Sabrina, what kind of impact could this have on the timing of the readout? you know, are we Just to get a sense as to whether this is a matter of just a couple of months or whether it's potentially something more significant than that? Thank you. Yeah. No, that's a fantastic question. If you're just doing the simple math, right, 250 women completing 13 cycles, right? That's a lot more, not a lot more, but it's more than 2,500 cycles or 250 women completing 12 months, right? Might be the easier way to do it, the math quick in your head. Obviously, it makes a difference. You know, what you're looking for with a product like this, I mean, part of the reason, right, in clinical development we have targets is you don't know what you're going to see from a safety signal, what you might see over time. Ovaprene is very much a first-in-category product. It's the first ever once-a-month vaginal product, non-hormonal vaginal product, that women are experiencing. You know, what's exciting about the data that we've seen to date, and having the DSMB look at it is that we're not seeing a change in that safety signal over time. We're not seeing, you know, any modifications in terms of types of adverse events or when they're happening over the course of the women that have completed the 13 cycles to date. Yes, it can make a difference in terms of timing of, you know, completing the follow-up with the women in terms of timing in 2027, right, when we could be able to target that readout. At this point, I can't give you more specific insights than that. You know, we do want to engage with the FDA on what we've seen now because we think it's really promising and, you know, we'd love to share it with them and get their perspective. Okay, t hat's fair enough. Thank you. Switching to DARE to PLAY, you know, the launch has slipped some as we've gone along. It looks like you're now closer to the finish line. You know, what have been the factors that have impacted the timing of, you know, getting to the point where you can do nationwide fulfillment? Yeah. You know, we're really trying to work closely with our partner, I refer to them as partner, but the 503B outsourcing facility, Bravado, that really is doing the work, right? They're the ones doing the manufacturing. They're the ones really that have to ensure that they're commercially ready. That obviously, you know, involves just GMP, right, good manufacturing practices, you know, having the readiness to supply the product and meet commercial demand, obviously critical. The other piece of it, though, is state-specific registration activities that a 503B outsourcing facility is required to do. They've been doing a fantastic job with that. Most 503B facilities are not registered across the country, they have been going through that process. They're up to, I think it's 28 or so, you know, registrations at this time. It's really balancing all of those factors and, you know, we want to prioritize doing this right, and making sure that when the product becomes commercially available via the dispensing, that everything's ready on the Bravado side to ensure that they can have that quality and consistency of supply and that it's meeting the demand. That's really what it's, you know, coming down to, and that as many women, you know, when it becomes commercially available initially, that as many women across the country can access it as possible. There are some states that simply will not allow dispensing in their state until they can review data from other states, you know, showing like shipping and quality standards. There are some states that are going to be a little behind, but you know, that's all what's behind it. Okay, great. Thank you. I'll let someone else jump in. Thanks for the questions. Thank you so much. Again, if you would like to ask a question, press star, one on your telephone keypad. We will pause for a brief moment to wait for the questions to come in. Thank you. Our next question comes from the line of Kemp Dolliver from Brookline Capital Markets. Please go ahead. Thanks for taking the follow-up. Just quickly, how are you thinking about the cash runway at this point? Yeah. As we said in the 10-Q, when you get to the details on that, you know, our cash, we have cash that's for grant-funded activities, right, because we have a lot of grant funding that we receive for a number of our programs, and then cash that, you know, we can use for general operating activities. Without the impact of obviously any of these revenue opportunities that we're talking about, if you just like looked in a vacuum at where we are on cash, you know, we will need to raise. We don't have 12 months of capital from that perspective. You know, it's always something that we're looking at. Obviously, that doesn't take into consideration the revenue inflows that we project for the products, that's just cash in hand today without any of that looking. Also, the other piece of it is the grant-funded activities, you know, those activities, there's always a kind of future disbursements that come with those grants as well. I know sometimes it's confusing when people are looking at our cash, you know, and our grant liability to try to understand where things are. Some of it's, you know, it's the GAAP accounting piece of it, that means things don't always line up. Those are the two ways we use our capital. It's for the grant-funded activities, and then it's for operations like supporting the DARE to PLAY launch, supporting DARE to RESTORE. It's fair to say it's at least a couple. It may not be 12 months, but it's a couple of quarters. Yes. Great. Thank you. Thank you. That concludes the question- and- answer session. I would like to turn the call back over to Sabrina Martucci Johnson for closing remarks. Please go ahead. Absolutely. Thank you. Well, thank you everyone for participating today. As we've talked a little bit about, you know, women's health has been dismissed, it's been deprioritized, it's been underfunded for generations. The conditions that we address at Daré, arousal, vaginal health, menopause, contraception, HPV, these affect hundreds of millions of women worldwide. They're not rare diseases. They're common experiences that have been met far too often with inadequate options, clinical dismissal, or simply nothing at all. We're founded on the belief that women deserve better, and that belief has guided every decision we've made, including the decision to be a product company, to do the hard, rigorous work of developing the clinical data and building formulations that providers and patients can trust. That choice was deliberate. Clinician and patient awareness of DARE to PLAY is growing. As I mentioned, we saw those providers at ACOG who are already writing prescriptions and asking us how to stock the product in their offices. As we just mentioned, dispensing is targeted for this summer, the Flora Sync LF5, the seeding campaigns, they're beginning, commercial launch and first product revenue is targeted for June. We talked a lot about that interim data from our Ovaprene phase III trial that we just received, that second consecutive DSMB review. You know, Ovaprene's a product that could be the first FDA-approved hormone-free monthly contraceptive. I highlighted a few things about the pipeline behind it, which is deep and differentiated and advancing. A commercial company and an R&D company. We're entering a phase where both are true for us simultaneously, and where product revenue becomes just one more source of capital to fund the science that will produce the next generation of solutions that will in turn generate revenue. That's the model working exactly as we designed it. You know, we built the company to change how women experience healthcare, and that change is beginning in earnest right now. I just thank all of you for your confidence and for being owners. We believe the assets we hold, the catalysts ahead, and the window of time we're in represent a compelling opportunity, and we intend to execute on it. June 2026 may be the month investors look back on as the moment that we became that revenue stage company, and without ever s topping being a science-driven one. Thank you for your time today, and I look forward to keeping you updated. Thank you so much. Ladies and gentlemen, this concludes today's call. Thank you all for joining. You may now disconnect.